A multicentre prospective randomized trial.~Hypothesis:~The discontinuation of anti-TNF treatment in inflammatory bowel disease (IBD) patients in clinical remission is associated with an increased risk of recurrence compared with maintaining such treatment.~Main objective:~To assess the percentage of patients with IBD who, after stopping anti-TNF treatment, have sustained clinical remission at one year compared to those in which the treatment is continued at stable doses~Secondary objectives:~To compare treatment discontinuation vs. treatment continuation of anti-TNF agents in patients with Crohn´s disease or ulcerative colitis in terms of:~remission (relapse-free) time,~phenotype changes with both strategies~mucosal healing,~radiologic healing~impact on quality of life and productivity~safety~to identify relapse predictive factors.~To identify relapse predictive factors after anti-TNF drug discontinuation~Determining the profile of serum cytokines in patients with both strategies, depending on drug exposure and if maintained clinical remission or relapse.~Planned number of subject to be included: 194~The participation of at 50 hospitals in Spain with an inclusion of about 5 patients per hospital is required..~Case report Form was designed on REDCap (a free, secure, web-based application designed to support data capture for research studies).
This study will be a multicentre prospective randomized trial to assess the percentage of patients with IBD who, after stopping anti-TNF treatment, have sustained clinical remission at one year compared to those in which the treatment is continued at stable doses